Cybin Inc. (HELP)

Helus Pharma: An Undervalued Psychedelic Platform Approaching A Major Catalyst

Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board

Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights

Helus Pharma Appoints Michael Halstead as Chief Executive Officer

Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

Helus Pharma: APPROACHing Inflection: Pivotal Readout Sets Up Asymmetric Upside

Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results

Cybin: A Speculative Bet On Their Pivotal Depression Readout

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year

Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering

Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering

Helus Pharma™ Announces US$50 Million Underwritten Offering

Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress

Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference

Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York